Alexion Pharmaceuticals
352 Knotter Drive, Cheshire, CT, 06410, United States
Overview
Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 8
Sector focus
- Biotechnology
- Health Care
- Medical
- Therapeutics
Investment portfolio
- Caelum Biosciences
Led · Equity · Jan 2019
Caelum Biosciences is a clinical‑stage biotechnology company founded by Fortress in January 2017 focused on treatments for rare and life‑threatening diseases. Its lead asset, CAEL‑101, is a first‑in‑class monoclonal antibody designed to bind insoluble light‑chain amyloid fibrils and reduce or eliminate organ amyloid deposits. Phase 1a/1b data in 27 relapsed and refractory AL amyloidosis patients showed improved cardiac and renal function and support the antibody’s potential to promote amyloid resolution. CAEL‑101 has received Orphan Drug Designation from the U.S. FDA (also as a radio‑imaging agent in AL amyloidosis). Under a strategic agreement with Alexion, Caelum will conduct development through the end of Phase 2 and remain responsible for manufacturing while Alexion collaborates on program design. Fortress remains a significant shareholder and retains economic upside tied to a possible Alexion acquisition.
- Moderna
Participated · Equity · Jan 2015
Moderna is building a broad portfolio of vaccines while advancing a late-stage clinical pipeline. The company plans to grow its seasonal vaccine offering from three approved products today to as many as six by 2028. Management projects that total revenue will rise 10 % in 2026. Cash generated from existing vaccine products is earmarked for investment in oncology and rare disease programs, laying the groundwork for further growth in 2027 and 2028. Early-stage pipeline investments are expected to begin maturing in 2029 and beyond. Access to newly secured credit strengthens the firm’s liquidity to support these initiatives.